Litigation Details for JM Smith Corporation v. AstraZeneca Pharmaceuticals L P (S.D.N.Y. 2019)
✉ Email this page to a colleague
JM Smith Corporation v. AstraZeneca Pharmaceuticals L P (S.D.N.Y. 2019)
| Docket | ⤷ Sign Up | Date Filed | 2019-08-02 |
| Court | District Court, S.D. New York | Date Terminated | 2020-08-11 |
| Cause | 15:15 Antitrust Litigation | Assigned To | Colleen McMahon |
| Jury Demand | Plaintiff | Referred To | |
| Patents | 6,923,984 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in JM Smith Corporation v. AstraZeneca Pharmaceuticals L P
The small molecule drug covered by the patent cited in this case is ⤷ Sign Up .
Details for JM Smith Corporation v. AstraZeneca Pharmaceuticals L P (S.D.N.Y. 2019)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2019-08-02 | 1 | Complaint | which are described in U.S. Pat. No. 6,923,984, incorporated herein by reference.36 …follow-on patent purportedly covering Seroquel XR, U.S. Patent No. 5,948,437 (the “’437 Patent”), which… is the owner of U.S. Patent No. 4,879,288 (“the ‘288 Patent”). The ’288 Patent issued on November 7,…’637B Patent. By issuing the Handa ’637A Patent and Handa ’637B Patent despite AstraZeneca’s ’288 and…637A Patent and in the Handa ’637B Patent were patentably distinct from the compositions disclosed and | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
